Raymond James Financial’s 2seventy bio TSVT Stock Holding History

Raymond James Financial’s Portfolio TSVT Stock Details TSVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-17,547	Closed	-$51.6K	–	4961
2024 Q4	$51.6K	Buy	+17,547	New	+$72K	﹤0.01%	4605

Other funds holding TSVT

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Raymond James Financial's TSVT Position: Q1 2025 in Review

Raymond James Financial sold out of 2seventy bio (TSVT) in Q1 2025, closing a stake of 17,547 shares — an estimated $51.6K sold.

Raymond James Financial first reported a position in TSVT in Q4 2024 and held it in 1 quarter. The position peaked at $51.6K in Q4 2024. 139 funds tracked by Wall St. Rank hold TSVT as of Q1 2025.

Raymond James Financial reported no remaining 2seventy bio position as of Q1 2025 after selling out during the quarter.
Raymond James Financial sold 17,547 2seventy bio shares in Q1 2025, an estimated $51.6K.
Raymond James Financial first reported a position in 2seventy bio in Q4 2024 and held it in 1 quarter.
Raymond James Financial's 2seventy bio position peaked at $51.6K in Q4 2024.
139 funds tracked by Wall St. Rank held 2seventy bio as of Q1 2025.

Based on Raymond James Financial's 13F filing for Q1 2025, filed 13 May 2025.